{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+200+mg%2Fm%5E2&page=3", "query": { "intervention": "temozolomide 200 mg/m^2", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+200+mg%2Fm%5E2&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+200+mg%2Fm%5E2&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T17:39:39.132Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03463265", "title": "Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" }, { "name": "nab-sirolimus + temozolomide", "type": "DRUG" }, { "name": "nab-sirolimus + bevacizumab", "type": "DRUG" }, { "name": "nab-sirolimus + lomustine", "type": "DRUG" }, { "name": "nab-sirolimus + marizomib (MRZ)", "type": "DRUG" }, { "name": "nab-sirolimus + temozolomide + radiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-08-01", "completion_date": "2022-08-26", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 3, "location_summary": "Fullerton, California • Newport Beach, California • Santa Monica, California", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03463265" }, { "nct_id": "NCT01409174", "title": "IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Interferon Alfa-2b", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2013-02", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409174" }, { "nct_id": "NCT06639607", "title": "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma", "Diffuse Midline High-grade Glioma", "Medulloblastoma", "Ependymoma" ], "interventions": [ { "name": "PEP-CMV vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus booster", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "4 Years to 25 Years" }, "enrollment_count": 68, "start_date": "2026-09-30", "completion_date": "2051-06-30", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 3, "location_summary": "St Louis, Missouri • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06639607" }, { "nct_id": "NCT00943826", "title": "A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 921, "start_date": "2009-06-29", "completion_date": "2015-09-09", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943826" }, { "nct_id": "NCT06428045", "title": "STARLITE for Unresectable High-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Glioma" ], "interventions": [ { "name": "Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)", "type": "PROCEDURE" }, { "name": "Abacavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Focal Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-04-15", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428045" }, { "nct_id": "NCT00112502", "title": "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2005-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 12, "location_summary": "Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112502" }, { "nct_id": "NCT02340156", "title": "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "RECURRENT GLIOBLASTOMA" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-12", "completion_date": "2018-11", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340156" }, { "nct_id": "NCT04757662", "title": "Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Grade III Astrocytoma", "Grade IV Astrocytoma", "Astrocytoma, Grade IV", "Astrocytoma, Grade III" ], "interventions": [ { "name": "Tadalafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-05-14", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2023-06-13", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757662" }, { "nct_id": "NCT00402116", "title": "Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2006-09", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402116" }, { "nct_id": "NCT00887146", "title": "Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "concomitant temozolomide (TMZ)", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "procarbazine", "type": "DRUG" }, { "name": "adjuvant temozolomide (TMZ)", "type": "DRUG" }, { "name": "CCNU", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2009-09", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-10T17:39:39.132Z", "location_count": 271, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887146" } ] }